Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 8, 2023
Discovery & Translation
Modalities, not targets, drive translational innovation at ASCO23
BioCentury’s analysis of first-in-human studies at ASCO 2023
BioCentury | Dec 3, 2021
Distillery Therapeutics
Computational identification of cancer compounds for PAH
BioCentury | Oct 23, 2020
Product Development
What’s next for targeted protein degradation
As the technology goes mainstream, next-gen molecules will use new enzymes, tap new pathways, and address PK/PD challenges
Items per page:
1 - 5 of 5